Sema Mandal

Sep 23, 2024 | bmj.com | Nick Andrews |Sema Mandal

Nick Andrews, statistician, Sema Mandal, consultant epidemiologist UK Health Security Agency, London, UK Correspondence to: N Andrews nick.andrews{at}ukhsa.gov.uk Further evidence of benefit from a target trial emulation study The modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine, originally developed to protect against smallpox, was introduced in 2022 to help tackle the large mpox outbreak caused by the clade IIb virus, which by August of that year had affected a total of 30 000...

Oct 17, 2023 | sti.bmj.com | Matt Hibbert |Ruth Simmons |Natasha Ratna |Sema Mandal

DiscussionVaccination coverage among FSW attending SHS is low; our analysis shows that only 37% of FSW attending SHS have a recorded HBV vaccination. Despite guidelines recommending offer of HBV vaccination to all FSW,6 uptake of vaccination was only 30% among those first recorded as FSW over the study period and varied by ethnicity, age, region of birth and region of residence.

Sep 11, 2023 | alphagalileo.org | Sema Mandal

The rapid outbreak of mpox (formerly known as monkeypox) in 2022 likely resulted from high levels of sexual mixing among some gay, bisexual and other men who have sex with men (GBMSM), with the initial downturn in cases probably due to a reduction in sexual contacts among these men, according to new research led by the National Institute for Health and Care Research (NIHR) Health Protection Research Unit [HPRU] in Behavioural Science and Evaluation.

Sep 11, 2023 | brnw.ch | Sema Mandal

The rapid outbreak of mpox (formerly known as monkeypox) in 2022 likely resulted from high levels of sexual mixing among some gay, bisexual and other men who have sex with men (GBMSM), with the initial downturn in cases probably due to a reduction in sexual contacts among these men, according to new research led by the National Institute for Health and Care Research (NIHR) Health Protection Research Unit (HPRU) in Behavioural Science and Evaluation.

Sep 11, 2023 | bristol.ac.uk | Sema Mandal

The paper, published in The Lancet Infectious Diseases today [11 September], also found that the scale-up in vaccination did not contribute much to the initial downturn in cases, although the very small number of cases in 2023 is likely due to sufficiently high vaccination coverage to prevent a widespread resurgence in cases.